The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may…
DIVO has raised its monthly payout three years running and sits on $5.25 billion in assets, but one holding carries a debt load that raises questions about how long the streak can…
Pfizer and Amgen both grew revenue last quarter at nearly the same pace, but the engines driving that growth point toward two very different futures in oncology. One company is collecting cash…
The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker:…
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech…
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave…
The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a…
Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN | AMGN Price Prediction) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1…
David Moadel Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR…
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) costs $6 a year on a $10,000 investment, holds 100 dividend stocks, and currently yields 3.39%. With the Fed funds rate sitting at 3.75% and most…
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech: “These are growth stocks where you don’t have to worry about disruption.…
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc. (NASDAQ:GILD | GILD Price Prediction) with a Buy rating and a $180 price target,…
Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday.…
If you have $10,000 that you won’t need to spend anytime soon, there are ways to derive passive income from that money. Among the easiest strategies is to buy and hold a…
Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its…
